REGISTER BY FEBRUARY 10 FOR EARLY EVENT PLATFORM ACCESS
- 00Days
- 00Hrs
- 00Mins
- 00Secs
Delivered as a Hybrid Event
February 27 - March 2, 2023San Diego Convention Centerkeyboard_arrow_right
Search & Filter keyboard_arrow_right
keyboard_arrow_left Hide
Main Conference - Day 3 - PST/PDT (Pacific Daylight, GMT-7)
keyboard_arrow_leftSearch & Filter
search
Streams
Formats
Main Conference - Day 3 - PST/PDT (Pacific Daylight, GMT-7)
search
Streams
Formats
8:00am - 8:25am25 mins
Coffee and Registration
8:25am - 8:30am5 mins
Cell Line Development & Engineering
Chairperson's Remarks
8:25am - 8:30am5 mins
Cell Culture
Chairperson's Remarks
8:25am - 8:30am5 mins
Recovery & Purification
Chairperson's Remarks
8:25am - 8:30am5 mins
Manufacturing Strategy & Bioprocessing 4.0
Chairperson's Remarks
- Keith Davis - Principle Scientist, ARD, Biotherapeutics Pharm Sci.,, Pfizer
8:25am - 8:30am5 mins
Next Generation CAR & T Cell Therapies
Chairperson's Remarks
8:30am - 9:00am30 mins
Cell Line Development & Engineering
Microfluidic chip-based single-cell cloning to accelerate biologic production timelines
- Jonathan Diep - Process Development Sr. Scientist Cell Line Development, Amgen
8:30am - 9:00am30 mins
Cell Culture
Adaptation of a Perfusion Platform to Mammalian Cell Lines of Different Host Lineages
- Gabriel Lurz - Senior Research Associate, CCD, Sanofi
8:30am - 9:00am30 mins
Recovery & Purification
Multi-Dimensional Real Time Monitoring and Accelerated Process Development in Downstream Processing Based on Predictive Models
- Astrid Dürauer - Laboratory of Protein Technology and Downstream Processing, Departement of Biotechnology, BOKU Vienna
8:30am - 9:00am30 mins
Manufacturing Strategy & Bioprocessing 4.0
Optimizing Tech Transfer Through Process Influence and Early Engagement
- Ryan Hogan - Associate Director, MS&T, AstraZeneca
8:30am - 9:00am30 mins
Next Generation CAR & T Cell Therapies
The Future of Genetic Medicine: What Will Products Look Like and How Will They be Manufactured?
- Carlos Ibañez, PhD - Founder, Chief Technology Officer, Abintus Bio
8:55am - 9:00am5 mins
Cell & Gene Therapy Manufacturing
Chairperson's Remarks
9:00am - 9:30am30 mins
Cell Line Development & Engineering
Cell Line Development for Bispecific Molecules: Random vs Targeted Integration
- Valentina Ciccarone, Ph.D. - Director, Cell Line Development, MacroGenics, Inc.
9:00am - 9:30am30 mins
Cell Culture
Raman for Glucose and Feedback Control
- Anita Kundu - Scientist, AstraZeneca
9:00am - 9:30am30 mins
Recovery & Purification
Scale Down Model Qualification – A Case Study on Implementation of Platform Approach Across Multiple Modalities
- Stacy Turner - Scientist, KBI Biopharma
9:00am - 9:30am30 mins
Manufacturing Strategy & Bioprocessing 4.0
A Case Study - Quality Culture and Site Transformation
- Sigma Mostafa, PhD - Senior Vice President and Site Head, KBI Biopharma
9:00am - 9:30am30 mins
Cell & Gene Therapy Manufacturing
Closure Analysis of a Mock Autologous Cell Therapy Process
- Carlos Gonzalez - Senior Engineer I, Alexion, AstraZeneca Rare Disease Unit , U.S.
9:00am - 9:30am30 mins
Next Generation CAR & T Cell Therapies
Decoding the immune system: the key to advancing cell therapy R&D
- Catherine Sanders, PhD - VP, Research and Business Development, Adaptive Biotechnologies
9:30am - 10:00am30 mins
Cell Line Development & Engineering
AI + Bioprocessing: Cell Line Development, Cell Culture Media Development, and Antibody Design
- Michael Chen, PhD - CEO & Co-founder, Great Bay Bio
9:30am - 10:00am30 mins
Cell Culture
Scientific Track Presentation
9:30am - 10:00am30 mins
Recovery & Purification
Scientific Track Presentation - A Representative from Avantor
9:30am - 10:00am30 mins
Manufacturing Strategy & Bioprocessing 4.0
Site Transfer of a Commercially Approved mAb: Recipe for Successful Tech Transfer
- Madhav Paranandi - Sr. Director, MSAT, Kemwell Biopharm
9:30am - 10:00am30 mins
Cell & Gene Therapy Manufacturing
Scientific Track Presentation
9:30am - 10:00am30 mins
Next Generation CAR & T Cell Therapies
Scientific Track Presentation
10:00am - 11:00am60 mins
Networking Refreshment Break in the Exhibit & Poster Hall
11:00am - 11:30am30 mins
Cell Line Development & Engineering
Please Move To Another Track
11:00am - 11:30am30 mins
Cell Culture
Cell-Free Systems - Specific Presentation Title TBD
- David Burgenson - Scientist, Sutro Biopharma
11:00am - 11:30am30 mins
Recovery & Purification
Continuous Bioseparations, and the Use of In Silico Process Development Tools to Aid in the Intelligent Design of These Downstream Processes for Non-mAb Biologics
- Nicholas Vecchiarello, PhD - Assistant Professor, Department of Chemical Engineering, University of Virginia
11:00am - 11:30am30 mins
Manufacturing Strategy & Bioprocessing 4.0
Discovery to manufacturing in record time for Covid mAb
11:00am - 11:30am30 mins
Cell & Gene Therapy Manufacturing
Multiplying Strategic Partnerships to Enable the Automation and Scale-out of our Autologous Process
- Arnaud Deladeriere - Director of Process Development, Triumvira Immunologics Inc.
11:00am - 11:30am30 mins
Next Generation CAR & T Cell Therapies
VivoVec engineers T cells in vivo to mediate durable anti-tumor responses
- Ryan Larson - Vice President, Head of Immunology, Umoja Biopharma
11:30am - 12:00pm30 mins
Cell Line Development & Engineering
Cell Lines for Cultivated Meat: What we are learning?
- Somen Nandi - Adjunct Professor, Chemical Engineering, University of California, Davis
11:30am - 12:00pm30 mins
Cell Culture
Cell-Free Systems - Specific Presentation Title TBD
- Michael Jewett - Walter P. Murphy Professor, Northwestern University
11:30am - 12:00pm30 mins
Recovery & Purification
Modernizing Downstream Process Development with Automated Solution Preparation, In-Line Process Analytical Tools, and High Throughput Approaches
- Rui Ye - Senior Scientist, Downstream Group, KBI Biopharma
11:30am - 12:00pm30 mins
Manufacturing Strategy & Bioprocessing 4.0
FFEATURED PRESENTATION: Digital Ecosystem for Cell Therapy Manufacturing Platform
- Oliver Hesse - VP & Head of Biotech Data Science & Digitalization, Bayer
11:30am - 12:00pm30 mins
Cell & Gene Therapy Manufacturing
Development of a Robust Manufacturing Process for AB-1015, an Integrated Circuit T Cell (ICT) Product, Using Targeted, CRISPR Integration of Transgenes by Electroporation (CITE) Editing
- Jenessa Smith - Director, Process Development, Arsenal Biosciences
11:30am - 12:00pm30 mins
Next Generation CAR & T Cell Therapies
A Powerful Platform to Find TCRs to Defined Targets: Applications in Allogeneic Stem Cell Transplantation
- Robert Keefe - Chief Development Officer, BlueSphere Bio
12:00pm - 12:30pm30 mins
Cell Line Development & Engineering
Scientific Track Presentation
12:00pm - 12:30pm30 mins
Cell Culture
Scientific Track Presentation
12:00pm - 12:30pm30 mins
Recovery & Purification
Scientific Track Presentation
12:00pm - 12:15pm15 mins
Manufacturing Strategy & Bioprocessing 4.0
Challenges and opportunities in developing a fully integrated continuous manufacturing process
- Himanshu Gadgil, Ph.D - CEO, Enzene Biosciences Ltd.
12:00pm - 12:15pm15 mins
Cell & Gene Therapy Manufacturing
Faster titer analysis with automated immunoassays - Case study from a process development lab
- Maria Germana Sanna, Ph.D. - Field Application Scientist, Gyros Protein Technologies
12:00pm - 12:30pm30 mins
Next Generation CAR & T Cell Therapies
Scientific Track Presentation
12:15pm - 12:30pm15 mins
Manufacturing Strategy & Bioprocessing 4.0
Scientific Track Presentation
12:15pm - 12:30pm15 mins
Cell & Gene Therapy Manufacturing
Scientific Track Presentation
12:30pm - 1:25pm55 mins
Luncheon in the Poster & Exhibit Hall
1:25pm - 1:30pm5 mins
Cell Line Development & Engineering
Chairperson's Remarks
1:25pm - 1:30pm5 mins
Cell Culture
Chairperson's Remarks
1:25pm - 1:30pm5 mins
Recovery & Purification
Chairperson's Remarks
1:25pm - 1:30pm5 mins
Manufacturing Strategy & Bioprocessing 4.0
Chairperson's Remarks
- Keith Davis - Principle Scientist, ARD, Biotherapeutics Pharm Sci.,, Pfizer
1:25pm - 1:30pm5 mins
Cell & Gene Therapy Manufacturing
Chairperson's Remarks
1:25pm - 1:30pm5 mins
Next Generation CAR & T Cell Therapies
Chairperson's Remarks
1:30pm - 2:00pm30 mins
Cell Line Development & Engineering
Population Dynamics, Phenotypic Heterogeneity, and Age: Shifting Expression Patterns in Stable and Unstable Clonally-Derived CHO Populations
- Theodore Peters, Ph.D. - Senior Scientist, Seagen
1:30pm - 2:00pm30 mins
Cell Culture
Impact of AAV ITR Design Upon AAV Production
- Andrew Tustian, EngD - Senior Director, Regeneron
1:30pm - 2:00pm30 mins
Recovery & Purification
Implications of AAV Affinity Column Reuse and Processing Conditions on Product Quality Attributes
- Harshal Soni - Graduate Student, Chemical and Biological Engineering, Rensselaer Polytechnic Institute
1:30pm - 2:00pm30 mins
Manufacturing Strategy & Bioprocessing 4.0
PAT in downstream bioprocessing
- Divya Chandra - Scientist, Merck
1:30pm - 2:00pm30 mins
Cell & Gene Therapy Manufacturing
Advanced Characterization to Support AAV Process Development
- Xiaoying Jin - Head of GMU BioAnalytics Characterization, Sanofi Global CMC Development
1:30pm - 2:00pm30 mins
Next Generation CAR & T Cell Therapies
Non-Viral Vector Engineered Allogeneic T Cell Therapies Utilizing a Novel Dimeric Antigen Receptor (DAR) Structure
- Wenzhong Guo - CTO, Cell Therapy, Sorrento Therapeutics, USA
2:00pm - 2:30pm30 mins
Cell Line Development & Engineering
Perfusion clone selection using a CSPR strategy in ambr15
- Christine Ferng - Senior Scientist, Astrazeneca
2:00pm - 2:30pm30 mins
Cell Culture
Use of dbDNA for the Production of AAV for Gene Therapy
- Felix Bastida, PhD - Scientific Director, TAAV
2:00pm - 2:30pm30 mins
Recovery & Purification
Evaluation of Continuous Countercurrent Tangential Chromatography (CCTC) for High Efficiency Column-Free Purification of AAVs
- Christopher Yehl - Process Development Scientist, Spark Therapeutics
2:00pm - 2:30pm30 mins
Manufacturing Strategy & Bioprocessing 4.0
Data Science & Machine Learning in the Move Towards Prescriptive Analytics
- Ramila Peiris - Director - Head of Data Science, Sanofi
2:00pm - 2:30pm30 mins
Cell & Gene Therapy Manufacturing
Establishment of a Replication Competent Assay for AAV8
- Aishwarya Shevade - Staff Engineer, Regeneron Pharmaceuticals
2:00pm - 2:30pm30 mins
Next Generation CAR & T Cell Therapies
Identifying & Validating New Disease Targets for TCR-equipped Cellular Therapeutics
- Reagan Jarvis - CEO & Co-founder, Anocca, Sweden
2:30pm - 3:00pm30 mins
Cell Line Development & Engineering
Novel cell engineering platform for creating high-productivity cells for therapeutic protein production, and for other purposes
- Larry Foreman - CEO, CHO PLUS
2:30pm - 3:00pm30 mins
Cell Culture
Optimizing Scale Up of AAV Gene Therapy in Upstream Processing
- Silvia Gomez Puerta - MSAT Head, Viralgen Commercial Therapeutic Vector Core
2:30pm - 3:00pm30 mins
Recovery & Purification
Harnessing AAV Technology and Manufacturing Capabilities to Meet the Needs of the Gene Therapy Market
2:30pm - 3:00pm30 mins
Manufacturing Strategy & Bioprocessing 4.0
Challenges Associated with Implementing In-line MALS (Multi Angle Light Scattering) Analysis, for Real-time Bioprocess Feedback and Control
- Keith Davis - Principle Scientist, ARD, Biotherapeutics Pharm Sci.,, Pfizer
2:30pm - 3:00pm30 mins
Cell & Gene Therapy Manufacturing
Approach to Particulate Control Strategy for Cell and Gene Therapy Product Manufacture
- Irina Kadiyala - Senior Director/ Head, Heme Process Development, Vertex Cell and Gene Therapies, Vertex Pharmaceuticals
2:30pm - 3:00pm30 mins
Next Generation CAR & T Cell Therapies
TAC-T Cells: Fulfilling the Promise of T Cell Therapy
- Paul Lammers - CEO, Triumvira Immunologics
Get the latest event updates
Sign up to get the latest event updates and information.
Filter
Streams
Formats